Controversies in drug allergy: Consensus documents from the world experts - 04/01/19
Doi : 10.1016/j.jaci.2018.10.014
Michael Schatz, MD, MS a, ⁎ 
, Alessandro Fiocchi, MD b, Erika Jensen-Jarolim, MD c, Zuhair K. Ballas, MD d
, Alessandro Fiocchi, MD b, Erika Jensen-Jarolim, MD c, Zuhair K. Ballas, MD d a Kaiser Permanente Medical Center, San Diego, Calif
b Hospital Bambino Gesù in Rome, Vatican City, Italy
c Medical University Vienna and Messerli Research Institute, Vienna, Austria
d University of Iowa and the Iowa City VA, Iowa City, Iowa
∗Corresponding author: Michael Schatz, MD, MS, Kaiser Permanente Medical Center, Department of Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111.Kaiser Permanente Medical CenterDepartment of Allergy7060 Clairemont Mesa BlvdSan DiegoCA92111
Le texte complet de cet article est disponible en PDF.
| Published on behalf of the American Academy of Allergy, Asthma & Immunology and the World Allergy Organization. Copublished in the Journal of Allergy and Clinical Immunology: In Practice; the Journal of Allergy and Clinical Immunology; and the World Allergy Organization Journal. |
|
| Disclosure of potential conflicts of interest: M. Schatz declares no relevant conflicts of interest. A. Fiocchi is a member of various boards, none related to the current article, and has received lecture fees, none related to the current article. E. Jensen-Jarolim is on the Advisory Board for Bencard, Germany/Austria; has received consultancy fees from Bencard and Dr. Schärr; has received lecture fees from Bencard, Allergy Therapeutics, Novartis, Meda, Roxall, Biomedical Int., and ThermoFisher; and is a shareholder in Biomedical International R+D, Vienna, Austria. Z. K. Ballas is on the Immune Deficiency Foundation board; has received consultancy fees from Checkmate Pharma; and receives royalties from UpToDate. |
© 2018
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 143 - N° 1
P. 82-83 - janvier 2019 Retour au numéro
Article précédent
- Next-generation anti–Staphylococcus aureus vaccines: A potential new therapeutic option for atopic dermatitis?
- Julianne Clowry, Alan D. Irvine, Rachel M. McLoughlin
- Indirect treatment comparisons and biologics
- David Mauger, Andrea J. Apter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?